**OBJECTIVE:** Muscle fibrosis is a devastating sequela following ischemia--reperfusion injury that results in significant functional impairment and poor outcomes. Directing the response to muscle injury from a profibrotic to a regenerative pathway would be of great clinical value. We hypothesize that macrophage-specific knockout of *Tgfb1* and preclinical ligand trap binding of transforming growth factor (TGF)-β1 in wild-type animals will reduce the development of muscle fibrosis and will increase regeneration of myofibers after injury with organized production of collagen by fibroadipogenic progenitor cells (FAPs).

**METHODS:** Ischemia was induced in the left hind limb of *LysMCre-Tgfb1*^*fx/fx*^ and age and strain-matched controls with clamping of the femoral vessels for 3 hours with simultaneous injection of cardiotoxin into the left tibialis anterior muscle. Left and right tibialis anterior muscles were harvested 1 week following injury. Histologic sections were stained with hematoxylin and eosin for morphology, picrosirius red for collagen quantification, and Masson's trichrome for fibrosis architecture. Picrosirius-stained slides were imaged and analyzed using ImageJ to measure positive collagen staining. Myovision software was used to calculate myofiber cross-sectional area and Feret diameter (n = 3 per group). Sections were stained for immunofluorescence for F4/80, PDGFR-α, and TGF-β1. Mean fluorescent area also calculated with ImageJ. Flow cytometry was performed to quantify macrophage, neutrophil, and monocyte markers (n = 4 each). Next, adaptive transfer of *LysmCre*^*mtmg*^ macrophages was performed into *LysMCre-Tgfb1*^*fx/fx*^ mice. Separately C57BL/6J mice were treated with a TGF-β1/3 ligand trap (TGF-βRII-Fc) or vehicle following IR cardiotoxin (n = 3 each). Similar analyses performed as described above.

**RESULTS:** *LysMCre-Tgfb1*^*fx/fx*^ mice demonstrated significantly less fibrosis and muscle injury compared to controls. We found significantly higher area of fibrosis by picrosirius red staining in C57BL6/J animals compared to *LysMCre-Tgfb1*^*fx/fx*^ which appeared uninjured, grossly similar to uninjured control (52.32 versus 13.39 μm^2^; *P* \< 0.0001). Immunofluorescence showed decreased macrophage infiltration (F4/80) at the injury site and organized PDGFR-α staining in *LysMCre*-*Tgfb1*^fx/fx^ injured muscle compared to wild-type (WT) mice. Flow cytometry revealed lower number of macrophages present in injured knockout muscle compared to WT. Adoptive transfer of LysmCre^mtmg^ macrophages recapitulated a fibrotic phenotype. TGF-βRII-Fc treatment of WT mice produced similar results to *Tgfb1* knockouts almost completely mitigating fibrosis as quantified by picrosirius red staining (57.29 versus 17.17 μm^2^; *P* \< 0.0001).

**CONCLUSIONS:** Our *LysMCre-Tgfb1*^*fx/fx*^ animals demonstrated markedly reduced muscle injury with no obvious areas of fibrosis. The presence of increased PDGFR-α interstitial staining in wild-type muscle compared to *LysMCre-Tgfb1*^*fx/fx*^ injured muscle suggests a disorganized proliferation of FAP cells within the wild-type injury site. The decrease in FAP proliferation in the *LysMCre-Tgfb1*^*fx/fx*^ muscle suggests that macrophage-derived TGF-β1 may induce FAP proliferation and without it, the response to injury may be more regenerative than profibrotic. Treatment with TGF-βRII-Fc ligand trap yielded similar results to knockout suggesting that it may offer a viable therapeutic agent for prevention of muscle fibrosis in ischemia--reperfusion injury.
